Please assess the completion status of the following clinical trial:

Trial Title: Immunology and Safety of Menactra® in Children in Saudi Arabia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Healthy, as determined by medical history and physical examination.~* Aged between 5 to 8 years on the day of inclusion (from 5th birthday to 1 day before 9th birthday inclusive).~* For the Booster Group , two doses of a quadrivalent (A, C, Y, W-135) meningococcal polysaccharide vaccine received before age 2 years~* For the Control Group , no previous history of any meningococcal vaccination~* Informed consent form signed by the parent(s) or other legal representative~* Able to provide a vaccination log or has available vaccination record in the Health Center.~* Able to attend all scheduled visits and to comply with all trial procedures~Exclusion Criteria :~* Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric, etc.)~* Known or suspected impairment of immunologic function.~* Acute medical illness with or without fever within the last 72 hours or a oral temperature ≥ 37.5°C at the time of inclusion.~* Administration of immune globulin or other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the trial vaccine. Individuals on a tapering dose schedule of oral steroids lasting \< 7 days may be included in the trial provided that they have not received more than one course within the last two weeks prior to enrollment.~* Oral or injected antibiotic therapy within the 72 hours prior to vaccination.~* Received any vaccine in the 14-day period prior to trial vaccination, or scheduled to receive any vaccination during the 14-day period after trial vaccination.~* Previous history of documented invasive meningococcal disease.~* For the Control Group, previous history of any meningococcal vaccination.~* Systemic hypersensitivity to any of the vaccines components or history of a life-threatening reaction to the trial vaccines or a vaccine containing the same substances.~* Participation in another clinical trial in the 4 weeks preceding the trial vaccination~* Planned participation in another clinical trial during the present trial period~* Any condition, which, in the opinion of the investigator, would pose a health risk to the subject, or interfere with the evaluation of the vaccine.~* Personal or family history of Guillain Barré syndrome.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 8 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: Menactra® Booster Group (Type: EXPERIMENTAL): Participants who had received 2 doses of quadrivalent (A, C, Y, and W-135) meningococcal polysaccharide vaccine before age 2 years received a booster vaccination with Menactra® vaccine.
- Group 2: Menactra® Primary Vaccine (Control) Group (Type: EXPERIMENTAL): Participants who had not previously been given any meningococcal vaccine (meningococcal vaccine naive) received a primary vaccination with Menactra® vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).